RE: “COMBINED POSTMENOPAUSAL HORMONE THERAPY AND CARDIOVASCULAR DISEASE: TOWARD RESOLVING THE DISCREPANCY BETWEEN OBSERVATIONAL STUDIES AND THE WOMEN'S HEALTH INITIATIVE CLINICAL TRIAL”
Open Access
- 26 April 2006
- journal article
- editorial
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 163 (11) , 1067-1068
- https://doi.org/10.1093/aje/kwj156
Abstract
We appreciate the effort by Prentice et al. (1) to elucidate the basis for differences in the relation of postmenopausal hormone therapy to risk of coronary heart disease in observational studies and in the Women's Health Initiative (WHI) trial. Three findings from this and earlier WHI reports (2–4) are key.Keywords
This publication has 8 references indexed in Scilit:
- Hormone Therapy and Coronary Heart Disease: The Role of Time since Menopause and Age at Hormone InitiationJournal of Women's Health, 2006
- Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical TrialAmerican Journal of Epidemiology, 2005
- KEEPS: The Kronos Early Estrogen Prevention StudyClimacteric, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Estrogen plus Progestin and the Risk of Coronary Heart DiseaseNew England Journal of Medicine, 2003
- Understanding the Divergent Data on Postmenopausal Hormone TherapyNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998